1.

Record Nr.

UNINA9910254273803321

Autore

Ting Naitee

Titolo

Phase II Clinical Development of New Drugs / / by Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri

Pubbl/distr/stampa

Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017

ISBN

981-10-4194-6

Edizione

[1st ed. 2017.]

Descrizione fisica

1 online resource (XVII, 241 p. 25 illus., 17 illus. in color.)

Collana

ICSA Book Series in Statistics, , 2199-0980

Disciplina

615.19

Soggetti

Statistics

Pharmaceutical technology

Management

Statistics for Life Sciences, Medicine, Health Sciences

Pharmaceutical Sciences/Technology

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di bibliografia

Includes bibliographical references at the end of each chapters.

Nota di contenuto

Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials.

Sommario/riassunto

This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.